CSPC Pharmaceutical Group Ltd (CSPC) is a pharmaceutical company, which provides innovative, generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
CSPC Pharmaceutical Group Ltd premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Capsules | Distribution of Pharmaceutical Products | Duomeisu |
Tablets | Research and Development | Oulaining |
Injections | Enxi | |
XYZ | XYZ | |
XYZ | XYZ | |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In March, the company secured clinical trial approval granted from the National Medical Products Administration of the People’s Republic of China to commence clinical trials in China for weight management in overweight adults or obese patients. |
2024 | Regulatory Approval | In February, the company received marketing approval for Mingfule (recombinant human TNK tissue-type plasminogen activator for injection) (rhTNK-tPA) (1.0×107 IU/16 mg/injection) by the National Medical Products Administration of the People’s Republic of China. |
2023 | Regulatory Approval | In November, the company's SYS-6011 secured approval from China’s National Medical Products Administration to enter clinical trials in China for solid tumors. |
Competitor Comparison
Key Parameters | CSPC Pharmaceutical Group Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Sino Biopharmaceutical Ltd | Zhejiang Medicine Co Ltd | China Medical System Holdings Ltd |
---|---|---|---|---|---|
Headquarters | China | China | Hong Kong | China | Hong Kong |
City | Shijiazhuang | Shanghai | Hong Kong | Shaoxing | Hong Kong |
State/Province | Hebei | Shanghai | - | Zhejiang | Guangdong |
No. of Employees | 23,500 | 40,370 | 25,806 | 6,208 | 5,701 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Cai Dongchen | Chairman | Executive Board | - | - |
Zhang Cuilong | Chief Executive Officer; Vice Chairman | Executive Board | 2022 | - |
Pan Weidong | Director | Executive Board | 2006 | - |
Wang Qingxi | Director | Executive Board | 2018 | - |
Li Chunlei | Director | Executive Board | 2017 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer